Actively Recruiting

Phase 2
Age: 18Years - 90Years
All Genders
NCT06706258

Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)

Led by The University of Texas Health Science Center, Houston · Updated on 2025-05-14

400

Participants Needed

1

Research Sites

126 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The central hypothesis of this research study is that perioperative administration of the proton pump inhibitor (PPI) pantoprazole could reduce the development of acute kidney injury (AKI) following cardiac surgery by activation molecular pathways for kidney protection. The investigators propose a single-center, randomized, controlled, single-blinded trial to determine whether perioperative intravenous administration of pantoprazole will reduce the incidence of AKI, some molecules that can be detected the urine, and major adverse kidney events (MAKE) at day 30 postoperatively, compared to famotidine after cardiac surgery. The specific aims of the study will be achieved by randomizing a group of 400 patients to receive pantoprazole (study) or famotidine (control) for 3 days perioperatively. Our study population will include any adult patients (aged over 18 years) scheduled for cardiac surgery requiring a cardiopulmonary bypass machine.

CONDITIONS

Official Title

Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients aged 18 to 90 years
  • Scheduled for elective cardiac surgery with cardiopulmonary bypass
  • Moderate to high risk of developing acute kidney injury (Cleveland risk score of 3 or higher)
Not Eligible

You will not qualify if you...

  • Patients with preoperative estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73 m2
  • Dialysis dependence
  • Emergency surgery
  • Pregnancy
  • Nursing patients
  • Patients with interstitial nephritis
  • Hypersensitivity to proton pump inhibitors
  • Liver disease
  • Vitamin B12 deficiency

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Memorial Hermann Texas Medical Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

Y

Yafen Liang, MD

CONTACT

S

Simon Betancourt Escobar, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here